Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128775 | 1.00 | NAAA (0.46) | NAAAEPHX1TSHRPPARGGBA2 | |
| SCHEMBL2128072 | 1.00 | NAAA (0.46) | NAAAEPHX1TSHRPPARGGBA2 | |
| SCHEMBL2129350 | 1.00 | NAAA (0.46) | NAAAEPHX1TSHRPPARGGBA2 | |
| SCHEMBL2127847 | 0.98 | NAAA (0.43) | NAAAEPHX1TSHRPPARGGBA2 | |
| SCHEMBL2129276 | 0.93 | ALDH1A1 (0.44) | NAAAEPHX1TSHRPPARGGBA2 | |
| SCHEMBL2128447 | 0.88 | LMNA (0.38) | TSHRHCAR2ALDH1A1LMNAESR1 | |
| SCHEMBL1150513 | 0.83 | ALDH1A1 (0.46) | NAAAEPHX1TSHRPPARGHCAR2 | |
| SCHEMBL1150187 | 0.81 | ALDH1A1 (0.47) | NAAAEPHX1TSHRPPARGHCAR2 | |
| SCHEMBL2127418 | 0.80 | LMNA (0.51) | TSHRALDH1A1LMNA | |
| SCHEMBL1150644 | 0.78 | LMNA (0.46) | NAAAEPHX1TSHRPPARGHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1535895-B1 | PROCESS FOR PRODUCTION OF FORMYLCYCLOPROPANECARBOXYLIC ESTERS | SUMITOMO CHEMICAL CO (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20050240050-A1 | Process for production of formylcyclopropanecarboxylic ester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1535895-A1 | PROCESS FOR PRODUCTION OF FORMYLCYCLOPROPANECARBOXYLIC ESTERS | Sumitomo Chemical Company, Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240050-A1 | Process for production of formylcyclopropanecarboxylic ester | AHCYL1, HACL2, CBR1 | NAAA 306/4885EPHX1 663/4885TSHR 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.